Dynamic Expansion and Contraction of Multiple Sclerosis T2-Weighted Hyperintense Lesions Are Present below the Threshold of Visual Perception

References

1. 1.↵
   1. Lebrun-Frenay C,
   2. Kantarci O,
   3. Siva A, et al

   . Radiologically isolated syndrome. Lancet Neurol 2023;22:1075–86 doi:10.1016/S1474-4422(23)00281-8 pmid:37839432

   CrossRefPubMed
2. 2.↵
   1. Filippi M,
   2. Preziosa P,
   3. Banwell BL, et al

   . Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 2019;142:1858–75 doi:10.1093/brain/awz144 pmid:31209474

   CrossRefPubMed
3. 3.↵
   1. McFarland HF,
   2. Frank JA,
   3. Albert PS, et al

   . Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758–66 doi:10.1002/ana.410320609 pmid:1471866

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Okuda DT,
   2. Moog TM,
   3. McCreary M, et al

   . Utility of shape evolution and displacement in the classification of chronic multiple sclerosis lesions. Sci Rep 2020;10:19560 doi:10.1038/s41598-020-76420-8 pmid:33177565

   CrossRefPubMed
5. 5.↵
   1. Trapp BD,
   2. Peterson J,
   3. Ransohoff RM, et al

   . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85 doi:10.1056/NEJM199801293380502 pmid:9445407

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Comi G,
   2. Kappos L,
   3. Selmaj KW, et al

   ; SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 2019;18:1009–20 doi:10.1016/S1474-4422(19)30239-X pmid:31492651

   CrossRefPubMed
7. 7.↵
   1. Cohen JA,
   2. Comi G,
   3. Selmaj KW, et al

   ; RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 2019;18:1021–33 doi:10.1016/S1474-4422(19)30238-8 pmid:31492652

   CrossRefPubMed
8. 8.↵
   1. Hauser SL,
   2. Bar-Or A,
   3. Cohen JA, et al

   ; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020;383:546–57 doi:10.1056/NEJMoa1917246 pmid:32757523

   CrossRefPubMed
9. 9.↵
   1. Steinman L,
   2. Fox E,
   3. Hartung HP, et al

   ; ULTIMATE I and ULTIMATE II Investigators. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 2022;387:704–14 doi:10.1056/NEJMoa2201904 pmid:36001711

   CrossRefPubMed
10. 10.↵
    1. Sivakolundu DK,
    2. Hansen MR,
    3. West KL, et al

    . Three-dimensional lesion phenotyping and physiologic characterization inform remyelination ability in multiple sclerosis. J Neuroimaging 2019;29:605–14 doi:10.1111/jon.12633 pmid:31148298

    CrossRefPubMed
11. 11.↵
    1. Sivakolundu DK,
    2. West KL,
    3. Zuppichini MD, et al

    . BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non-specific white matter disease: a three-dimensional approach. J Neurol 2020;267:2888–96 doi:10.1007/s00415-020-09923-z pmid:32468116

    CrossRefPubMed
12. 12.↵
    1. Moog TM,
    2. McCreary M,
    3. Stanley T, et al

    . African Americans experience disproportionate neurodegenerative changes in the medulla and upper cervical spinal cord in early multiple sclerosis. Mult Scler Relat Disord 2020;45:102429 doi:10.1016/j.msard.2020.102429 pmid:32805478

    CrossRefPubMed
13. 13.↵
    1. Moog TM,
    2. McCreary M,
    3. Wilson A, et al

    . Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease. J Neurol 2022;269:4459–68 doi:10.1007/s00415-022-11089-9 pmid:35380254

    CrossRefPubMed
14. 14.↵
    1. Okuda DT,
    2. Stanley T,
    3. McCreary M, et al

    . Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry. Mult Scler 2022;29:691–701 doi:10.1177/13524585221139575 pmid:36507671

    CrossRefPubMed
15. 15.↵
    1. Okuda DT,
    2. Stanley T,
    3. McCreary M, et al

    . Dorsal medulla surface texture: differentiating neuromyelitis optica spectrum disorder from multiple sclerosis. J Neuroimaging 2022;32:1090–97 doi:10.1111/jon.13059 pmid:36181675

    CrossRefPubMed
16. 16.↵
    1. Nyul LG,
    2. Udupa JK,
    3. Zhang X

    . New variants of a method of MRI scale standardization. IEEE Trans Med Imaging 2000;19:143–50 doi:10.1109/42.836373 pmid:10784285

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Caselles V,
    2. Kimmel R,
    3. Sapiro G

    . Geodesic active contours. Int J Comput Vis 1997;22:61–79 doi:10.1023/A:1007979827043

    CrossRef
18. 18.↵
    1. Cole TJ

    . The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990;44:45–60 pmid:2354692

    PubMedWeb of Science
19. 19.↵
    1. Cole TJ

    . Fitting smoothed centile curves to reference data. J R Stat Soc Ser A Stat Soc 1988;151:385–418 doi:10.2307/2982992

    CrossRef
20. 20.↵
    1. Hothorn T,
    2. Bretz F,
    3. Westfall P

    . Simultaneous inference in general parametric models. Biom J 2008;50:346–63 doi:10.1002/bimj.200810425 pmid:18481363

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Klistorner S,
    2. Barnett MH,
    3. Graham SL, et al

    . The expansion and severity of chronic MS lesions follows a periventricular gradient. Mult Scler 2022;28:1504–14 doi:10.1177/13524585221080667 pmid:35296170

    CrossRefPubMed
22. 22.↵
    1. Fisniku LK,
    2. Brex PA,
    3. Altmann DR, et al

    . Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808–17 doi:10.1093/brain/awm329 pmid:18234696

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Moraal B,
    2. Meier DS,
    3. Poppe PA, et al

    . Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology 2009;250:506–14 doi:10.1148/radiol.2501080480 pmid:19037018

    CrossRefPubMed
24. 24.↵
    1. Rahmanzadeh R,
    2. Galbusera R,
    3. Lu PJ, et al

    . A new advanced MRI biomarker for remyelinated lesions in multiple sclerosis. Ann Neurol 2022;92:486–502 doi:10.1002/ana.26441 pmid:35713309

    CrossRefPubMed
25. 25.↵
    1. Klistorner S,
    2. Barnett MH,
    3. Parratt J, et al

    . Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy. Ann Clin Transl Neurol 2022;9:1528–37 doi:10.1002/acn3.51644 pmid:36056634

    CrossRefPubMed
26. 26.↵
    1. Huynh TN,
    2. Johnson T,
    3. Poder L, et al

    . T1 pseudohyperintensity on fat-suppressed magnetic resonance imaging: a potential diagnostic pitfall. J Comput Assist Tomogr 2011;35:459–61 doi:10.1097/RCT.0b013e31822227c3 pmid:21765301

    CrossRefPubMed
27. 27.↵
    1. Adelson EH

    . Perceptual organization and the judgment of brightness. Science 1993;262:2042–44 doi:10.1126/science.8266102 pmid:8266102

    Abstract/FREE Full Text
28. 28.↵
    1. Fiedler A,
    2. Moore CM

    . Illumination frame of reference in the object-reviewing paradigm: a case of luminance and lightness. J Exp Psychol Hum Percept Perform 2015;41:1709–17 doi:10.1037/xhp0000123 pmid:26280265

    CrossRefPubMed
29. 29.↵
    1. Lotto RB,
    2. Williams SM,
    3. Purves D

    . Mach bands as empirically derived associations. Proc Natl Acad Sci U S A 1999;96:5245–50 doi:10.1073/pnas.96.9.5245 pmid:10220451

    Abstract/FREE Full Text
30. 30.↵
    1. Panikkath R,
    2. Panikkath D

    . Mach band sign: an optical illusion. Proc (Bayl Univ Med Cent) 2014;27:364–65 doi:10.1080/08998280.2014.11929161 pmid:25484514

    CrossRefPubMed
31. 31.↵
    1. Mazade R,
    2. Jin J,
    3. Rahimi-Nasrabadi H, et al

    . Cortical mechanisms of visual brightness. Cell Rep 2022;40:111438 doi:10.1016/j.celrep.2022.111438 pmid:36170812

    CrossRefPubMed
32. 32.↵
    1. Roe AW,
    2. Lu HD,
    3. Hung CP

    . Cortical processing of a brightness illusion. Proc Natl Acad Sci U S A 2005;102:3869–74 doi:10.1073/pnas.0500097102 pmid:15738406

    Abstract/FREE Full Text
33. 33.↵
    1. Albright TD,
    2. Stoner GR

    . Contextual influences on visual processing. Annu Rev Neurosci 2002;25:339–79 doi:10.1146/annurev.neuro.25.112701.142900 pmid:12052913

    CrossRefPubMedWeb of Science
34. 34.↵
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655 doi:10.1212/WNL.43.4.655

    Abstract/FREE Full Text
35. 35.↵
    1. Jacobs LD,
    2. Cookfair DL,
    3. Rudick RA, et al

    . A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995;1:118–35 doi:10.1177/135245859500100210 pmid:9345462

    CrossRefPubMed
36. 36.↵
    1. Johnson KP,
    2. Brooks BR,
    3. Cohen JA, et al

    . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268–76 doi:10.1212/wnl.45.7.1268 pmid:7617181

    Abstract/FREE Full Text
37. 37.↵
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498–504

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Montalban X,
    2. Arnold DL,
    3. Weber MS, et al

    ; Evobrutinib Phase 2 Study Group. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med 2019;380:2406–17 doi:10.1056/NEJMoa1901981 pmid:31075187

    CrossRefPubMed
39. 39.↵
    1. Reich DS,
    2. Arnold DL,
    3. Vermersch P, et al

    ; Tolebrutinib Phase 2b Study Group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2021;20:729–38 doi:10.1016/S1474-4422(21)00237-4 pmid:34418400

    CrossRefPubMed
40. 40.↵
    1. Sweeney EM,
    2. Nguyen TD,
    3. Kuceyeski A, et al

    . Estimation of multiple sclerosis lesion age on magnetic resonance imaging. Neuroimage 2021;225:117451 doi:10.1016/j.neuroimage.2020.117451 pmid:33069865

    CrossRefPubMed
41. 41.↵
    1. Weber CE,
    2. Wittayer M,
    3. Kraemer M, et al

    . Long-term dynamics of multiple sclerosis iron rim lesions. Mult Scler Relat Disord 2022;57:103340 doi:10.1016/j.msard.2021.103340 pmid:35158450

    CrossRefPubMed
42. 42.↵
    1. Bagnato F,
    2. Sati P,
    3. Hemond CC, et al

    . Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain 2024;147:2913–33 doi:10.1093/brain/awae013 pmid:38226694

    CrossRefPubMed
43. 43.↵
    1. Prineas JW,
    2. Connell F

    . Remyelination in multiple sclerosis. Ann Neurol 1979;5:22–31 doi:10.1002/ana.410050105 pmid:426466

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Kitzler HH,
    2. Wahl H,
    3. Kuntke P, et al

    . Exploring in vivo lesion myelination dynamics: longitudinal myelin water imaging in early multiple sclerosis. Neuroimage Clin 2022;36:103192 doi:10.1016/j.nicl.2022.103192 pmid:36162236

    CrossRefPubMed
45. 45.↵
    1. Galbusera R,
    2. Bahn E,
    3. Weigel M, et al

    . Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis. Brain Pathol 2023;33:e13136 doi:10.1111/bpa.13136 pmid:36480267

    CrossRefPubMed
46. 46.↵
    1. Hamzaoui M,
    2. Garcia J,
    3. Boffa G, et al

    . Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression. Ann Neurol 2023;94:366–83 doi:10.1002/ana.26657 pmid:37039158

    CrossRefPubMed